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Abstract Molecular insights from genome and systems biol-
ogy are influencing how cancer is diagnosed and treated. We
critically evaluate big data challenges in precision medicine.
The melanoma research community has identified distinct
subtypes involving chronic sun-induced damage and the
mitogen-activated protein kinase driver pathway. In addition,
despite low mutation burden, non-genomic mitogen-activated
protein kinase melanoma drivers are found in membrane re-
ceptors, metabolism, or epigenetic signaling with the ability to
bypass central mitogen-activated protein kinase molecules
and activating a similar program of mitogenic effectors.
Mutation hotspots, structural modeling, UV signature, and
genomic as well as non-genomic mechanisms of disease ini-
tiation and progression are taken into consideration to identify
resistance mutations and novel drug targets. A comprehensive
precision medicine profile of a malignant melanoma patient
illustrates future rational drug targeting strategies. Network
analysis emphasizes an important role of epigenetic and met-
abolic master regulators in oncogenesis. Co-occurrence of
driver mutations in signaling, metabolic, and epigenetic fac-
tors highlights how cumulative alterations of our genomes and
epigenomes progressively lead to uncontrolled cell prolifera-
tion. Precision insights have the ability to identify independent
molecular pathways suitable for drug targeting. Synergistic
treatment combinations of orthogonal modalities including
immunotherapy, mitogen-activated protein kinase inhibitors,
epigenetic inhibitors, and metabolic inhibitors have the
potential to overcome immune evasion, side effects, and drug
resistance.
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1 The impact of genomics and systems biology
on precision medicine
The emerging field of precision medicine has formalized our
wish for a fast, efficient, and accurate course of action to maxi-
mize health benefits (Fig. 1, Box 1). Data-driven science has
crossed over into the clinical realm. In an ideal world, precision
medicine decisions fit the patient’s needs like a key into a lock. In
cancer, each tissue is defined by a distinct molecular signature of
genomic and epigenomic changes. Therefore, leveraging
genome-wide and systems-wide insights for rational treatment
of cancer is the logical, inevitable next step towards data-
enhanced disease management and improved survival.
The availability of high-throughput omics data, including
deep sequencing of large patient cohorts, has challenged the
field of oncology to approach the disease from a holistic
systems-based perspective. In the past few years, systems biol-
ogy has matured as a field and has established rules to design
predictive, multiscale models. Such systems biology models
enable understanding of biochemical networks, discovery of
biomarkers, and patient stratification based on unique genomic
and non-genomic (e.g., transcriptomic, epigenomic, proteomic,
metabolic) profiles. However, without a mechanism to deter-
mine the underlying genetic cause of a set of symptoms, it
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might not be possible to decide which treatment will be most
effective a priori. Master regulators present distinct vulnerabil-
ities of networks. Their identification is crucial for systems-
based rational drug design as well as for disease management
by means of precision medicine. In a cyclic exercise, system
biologists derive synergy from complex, multidimensional
datasets by hypothesizing, testing, validating, improving, and
hypothesizing again to eventually arrive at the understanding
that biological networks are stronger than just a plain sum of
individual nodes. Cancer genome data has unlocked unprece-
dented opportunities for systems biology and helped to piece
together the puzzle of this complex disease. However, acquisi-
tion of cancer genome data is fast-paced and big data challenges
will need to be overcome in order to translate genomic insights
rapidly into new cancer therapies (Table 1).
The origin of malignant melanoma—similar to other can-
cers—is found in cumulative alterations of our genomes and
epigenomes progressively leading to uncontrolled cell prolif-
eration. By disrupting signals controlling cell division and
migration, such alterations may eventually lead to invasive
malignancies able to metastasize and populate distant sites.
Themolecular signatures of genomic and epigenomic changes
will provide insight as to why melanoma stands out as such a
serious and aggressive malignancy. Furthermore, this knowl-
edge will impact our perspective on how to approach melano-
ma prevention, diagnosis, and therapy. We will provide exam-
ples of how systems biology- and genome biology-driven ap-
proaches to cancer accelerate our ability to understand and
respond to malignant melanoma.
2 Melanoma genomics and big data challenges
in precision medicine
The field of melanoma genomics has experienced an expo-
nential rise over the past decade and has rapidly become a
paradigm for providing insight into melanoma driver
genes, cancer signaling, tumor immunology, and drug tar-
gets (Fig. 2). Next-generation sequencing technology has
made it possible to capture alterations by different plat-
forms and biological levels such as RNA-Seq tran-
scriptome analysis [1], sequencing of microRNAs
(miRNA-Seq) [2, 3], whole exome sequencing (WES) [4,
5], whole genome sequencing (WGS) [6–8], and chromatin
Fig. 1 Essential components in precision medicine and its application to
cancer. The precision medicine infrastructure relies on a fruitful interplay
between a a collaborative research team of clinicians and scientists, b
personalized data allowing for fast and seamless interpretation, and c
targeted pharmacological strategies. Precision disease management
comprises targeted, personalized treatment aligned with the patient’s
genotype offering confidence to receive/provide care and hope for cure.
In malignant melanoma, rational, orthogonal combinations of immune
checkpoint inhibitors (IMMUNOi), epigenetic inhibitors (EPIi),
metabolic inhibitors (METABi), or inhibitors of specific signaling
pathways such as the mitogen-activated protein kinase inhibitors
(MAPKi) will provide best standard of care. Balanced and effective
data sharing is based on patient consent, secure data exchange, and
synergistic, standardized data formats
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immunoprecipitation with next-generation sequencing
(ChIP-Seq) [9]. In addition, high-throughput single-nucle-
otide polymorphism (SNP) arrays [10, 11] have accelerated
progress in the field of somatic copy number alterations
(SCNAs) [12]. SCNAs can be captured either by low-
coverage WGS or SNP arrays [13].
The range of observed mutation rates within and across
tumor types spans more than five orders of magnitude
Fig. 2 Rate and challenges of cancer genomics studies with sequenced
tumors. a Sequenced and publically available cancer genomics studies
per year. The data contains cancer genomics studies with a total of more
than 20,000 whole exome sequenced or whole genome sequenced tumor
specimens. Exponential trend lines are based on current approximate
slope. Extrapolated data indicated by dashed line. b Exponential
increase and trend lines of whole genome and whole exome sequenced
specimens per year for melanoma and studies across all tissues (Pan-
cancer). c Melanoma specimens with high mutational burden carry
numerous somatic alterations and require somatic mutation calls at high
frequency. Depending on cancer tissue, cohort size, and mutational
burden, the dynamic range of somatic mutation calls can span several
orders of magnitude. Average trend lines are shown for different
cancers tissues with low (cyan), medium (blue), and high (purple)
mutational burden. Despite the fact that the currently available
melanoma cohort covers less than a tenth of all cancer tissues, the data
demands of somatic mutation calls in melanoma genomics are equally
challenging to that of other current cancer genomics studies combined
Table 1 Big data challenges in




Definition Big data challenges in precision medicine and cancer systems biology
Volume Data amount Complementary omics platforms generate terabytes of raw data for each
patient to be processed, analyzed, and interpreted.
Velocity Data in motion Necessity to acquire, process, share, stream, and compare data; otherwise,




Data in different formats and from different sources covers all levels of
biological information from genomics, epigenomics, transcriptomics,
proteomics, metabolomics, fluxomics, and phenomics.
Veracity Data with
uncertainty
Sample quality, heterogeneity, efficiency of alignment, data compatibility,
incompleteness, ambiguities, latency, deception, and model
approximations are factors contributing to uncertainty in data evaluation.
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(between 0.03 and 7000/Mbp) [14]. Melanoma was one of the
earliest tumor types sequenced, contributing to the forefront of
cancer genomics. The first comprehensive catalog of somatic
events was established by WGS on the metastatic COLO-829
cell line derived from a malignant melanoma patient [15].
Cancer genomics experienced a peak in 2012 (Fig. 2a), when
many studies from The Cancer Genome Atlas (TCGA) ma-
tured, publically funded by the National Cancer Institute
[16–18]. In a collaborative effort, thousands of tumor biopsies
were deposited in bio-specimen repositories, sequenced, proc-
essed at individual data levels, merged, and analyzed.
Similarly, the number of melanoma genomes sequenced broke
the hundreds in the same year [19–22]. However, the ability of
melanoma genomics to keep up with the pace and trends in
other cancer genomics fields was temporarily hampered by the
disproportionate data demands and frequent somatic mutation
calls (Fig. 2b, Box 1). In fact, the TCGA skin cutaneous mel-
anoma (SKCM) studies of 2015 required more somatic muta-
tion calls (average rate of 18/Mbp; many individual specimens
with rates above 1000/Mbp) than all other TCGA genomics
studies combined [13, 23] (Fig. 2c). The bioinformatics tool
Introns Vs Exons (InVEx) [20], designed to identify driver
genes by taking the specific background mutation rate per
patient and per gene into consideration, is currently the gold
standard in melanoma genomics. Genome-wide capture of
significant somatic events in melanoma is computationally
intensive. Currently, more than 700 melanoma specimens
with WES are available, comprising about 4% of the overall
cancer genomics efforts (Fig. 2a). Given the current 1.6-fold
increase in data production and exomes sequenced per year, it
is expected that soon cancer studies across all tissues can
accomplish 10,000s and melanoma studies 1000s of speci-
mens/year. Sharable data formats like oncotator will facilitate
future meta-studies of public and private melanoma genomics
efforts [24]. According to the saturation analysis of cancer
drivers, it will take more than 5000 specimens to reach more
than 99% power for a comprehensive catalog of cancer drivers
with intermediate mutation frequencies of 2–5% in melanoma
[14, 25]. Despite that the search for melanoma driver genes is
not saturated, the cancer research community has already
established a consistent set of high-frequency driver genes.
Today’s big biomedical data contains large, complex data
structures. In addition, comprehensive coverage requires dif-
ferent data levels, formats, and sources. V-type challenges
including volume, velocity, variety, and veracity (Table 1)
need to be overcome in order to link, match, cleanse, and
transform data across systems. Big data challenges are already
apparent at the molecular level for an individual patient when
looking at a precision medicine profile. Furthermore, interpre-
tation of precision medicine data for large patient cohorts re-
quires connection and correlation, hierarchies, and multilevel
linkages. Systems biology has the unique ability to connect
nucleotide or gene-based next-generation sequencing data
with other functional levels such as protein structures or me-
tabolite fragments acquired by high-throughput spectroscopy
or spectrometry methods. Tomorrow’s big data in precision
medicine requires savvy solutions to capture, curate, store,
share, maintain, update, query, and visualize data while main-
taining agreed privacy standards.
A successful approach to melanoma precision medicine
will take an integrated, seamless team effort of clinicians,
researchers, and providers (Fig. 1a). While genetic insights
are quickly adopted into the clinical decision-making process,
the infrastructure for genomics and precision medicine yet has
to be established. Deep sequencing efforts of melanoma spec-
imens are not well-integrated into the clinical routine, and
cohort-based genomics tools like GISTIC [26], MutSigCV
[27], or InVEx [20] are rather built for discovery research
[13] rather than day-to-day diagnostics. Patient consented data
sharing is necessary to securely exchange data between clin-
ical caretakers, biobanks, omics data acquisition platforms,
cloud-based processing, and genomics researchers. Not sur-
prisingly, conservative models of privacy were challenged
long before the advent of precision medicine by direct-to-
consumer genetic tests and population genome research pro-
jects [28–31]. Instead of relying on generalizable knowledge,
tomorrow’s repositories are moving towards fully consented
models motivated by a main benefit of being able to associate
longitudinal health records [32–34] (Fig. 1). A first step, the
rebranding of personalized medicine to precision medicine,
has been successfully undertaken and resulted in broad public
approval in contrast to the early rhetoric of personalized med-
icine [35]. Genomic and epigenomic testing will be a useful
tool to increase therapeutic success rates. Genetic markers
hold a well-defined probabilistic value, but when it comes
down to it, clinical implementation is important to address
ethical boundaries including stigmata of genetic determinism.
Reexamination and an update of ethical standards to catch up
with rapidly evolving innovations in precision medicine, fo-
rensics, and population genomics seem inevitable.
Early on, identification of activating point mutations in the
mitogen-activated protein kinase (MAPK) pathway in B-Raf
proto-oncogene (BRAF, serine/threonine kinase, Gene ID:
673) [36, 37] and neuroblastoma RAS viral oncogene homo-
log (NRAS, Gene ID: 4893) made it possible to match geno-
typed kinase mutations with precision medicine approaches
based on specific kinase inhibitors [38, 39]. Although
BRAF-activated melanomas initially have been the most suc-
cessful melanoma subset due to targeted therapies, they will
ultimately develop resistance and there is rapid progress in
complementary approaches especially ones taking advantage
of the immune system to fight cancer cells. In principle, mel-
anoma can be targeted from complementary angles, including
immune-checkpoint inhibitors (IMMUNOi) and/or targeted
therapy with inhibitors of specific signaling pathways such
as the mitogen-activated protein kinase inhibitors (MAPKi),
Cancer Metastasis Rev (2017) 36:91–108 95
epigenetic inhibitors (EPIi), or metabolic inhibitors
(METABi) (Fig. 1c).
The survival of advanced metastatic melanoma patients has
dramatically improved due to second-generation clinical trials
of melanoma drugs involving regimes with targeted therapy or
immune-checkpoint antibodies. For both groups, combinations
proved to be superior to single-agent regimens: Inhibition of
BRAF in combination with mitogen-activated protein kinase
kinase 7 (MAP2K7, MEK, Gene ID: 5609) improved survival
compared to single MAPKi [40–43]; blockade of combined im-
mune checkpoints by humanized antibodies improved survival
compared to single IMMUNOi of cytotoxic T-lymphocyte asso-
ciated protein 4 (CTLA4, Gene ID: 1493) with programmed cell
death 1 (PDCD1, PD1, CD279, Gene ID: 5133) or CD274 mol-
ecule (CD274, PDL1, PDCD1L1, Gene ID: 29126) [44–48]
(Table 2).
Specific small-molecule agents and respective trials in-
clude BRAF MAPKi: vemurafenib (PLX4032), dabrafenib
(GSK2118436), and encorafenib (LGX818) [38, 49–51];
MAP2K7 (MEK) MAPKi: trametinib (GSK-1120212) and
cobimetinib (GDC-0973) [39]; combination of BRAF and
MAP2K7 MAPKi [40–43, 52–54]; CTLA4 IMMUNOi:
ipilimumab (MDX-010) and tremelimumab (CP-675206),
[55–59]; PDCD1 (PD1) IMMUNOi: nivolumab (MDX-
1106, Opdivo) and pembrolizumab (MK-3475, Keytruda)
[60]; CD274 (PDL1) IMMUNOi: atezolizumab (Tecentriq);
and combinations of PDCD1 and CTLA4 IMMUNOi [44–46,
61].
Of single-agent therapies, conventional chemotherapy or
CTLA4 blockade showed poorest outcomes [62]. However,
pilot clinical data directly evaluating efficacy of combinations
of MAPKi and IMMUNOi is promising. Despite frequent
relapse and considerable side effects, targeted therapies show
a remarkable ability to suppress tumor growth and lead in
addition to a better functioning immune system [63]. This
may assist durable response of immunotherapy in future com-
bination trials involving MAPKi and IMMUNOi. It can be
foreseen that third-generation trials integrating precision med-
icine insights, new combinations or schedules, and the less
explored classes of EPIi and METABi will further improve
already efficacious regimens. In particular, cancer systems
biology offers insight into immunosuppressive effects of ge-
nomic, epigenomic, and metabolic drivers.
Because relapse, disease progression, or high rates of auto-
immune toxicity still need to be overcome, precision medicine
in cancer offers hope for better long-term benefits and reduced
side effects. While the clinical relevance of immune cells in
the control of human cancers is well established and genome
sequencing captures the somatic landscape, neoantigens that
arise as a consequence of tumor-specific mutations are a major
factor in the activity of immunotherapies [64–73]. Further,
neoantigens present themselves as targets for personalized
vaccines and cell therapies that target patient-specific cancer
mutations [74–79]. The identification of neoantigens can be
assisted by structure-based prediction or modeling approaches
[80]. Predictions of drug responses in melanoma will eventu-
ally improve by looking into gene expression signatures asso-
ciated with immune sensitivity or resistance [81].
3 Precision medicine profile of malignant melanoma
patient with BRAF, EZH2, and ARID signature
Genotyping has already replaced phenotyping in diagnosing
selected Mendelian disorders, neurologic syndromes, and in
prenatal or neonatal care [82, 83]. In cancer care, phenotype-
driven gene target definition is typical and clinical genome-
wide sequencing data interpretation is still accompanied by a
Table 2 Clinical trials with single-agent regimens or combinations of melanoma MAPKi and IMMUNOi drugs
Inhibitor Gene target Trials Drug name Compound PubChem Trade
MAPKi BRAF [38, 49–51] Vemurafenib PLX4032 CID: 42611257 Zelboraf
Dabrafenib GSK2118436 CID: 44462760
Encorafenib LGX818 CID: 50922675
MAPKi MAP2K7 (MEK) [39] Trametinib GSK-1120212 CID: 11707110
Cobimetinib GDC-0973 CID: 16222096
MAPKi Combination of BRAF and MEK inhibition [40–43, 52–54]
IMMUNOi CTLA4 [55–59] Ipilimumab MDX-010 SID: 131273201
Tremelimumab CP-675206 SID: 47208308
IMMUNOi PDCD1 (PD1) [60] Nivolumab MDX-1106 SID: 135341610 Opdivo
Pembrolizumab MK-3475 SID: 187051801 Keytruda
IMMUNOi CD274 (PDL1) Atezolizumab 1380723-44-3 SID: 312642102 Tecentriq
IMMUNOi Combination of PDCD1 and CTLA4 blockage [44–46, 61]
Current clinical trials utilize small-molecule mitogen-activated protein kinase inhibitors (MAPKi) or humanized antibodies as immune checkpoint
inhibitors (IMMUNOi). Molecules are referenced based on their unique PubChem chemical identifier CID or substance identifier SID
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large-scale research effort [84]. Here, we illustrate a complete
precision medicine profile of a malignant melanoma patient
[85] (Figs. 3 and 4). Cancer tissue image collections from a
variety of imaging modalities, including whole-slide tissue
images, computed tomography, magnetic resonance, X-ray,
or positron-emission tomography, allow pathologists to make
novel genotype-phenotype associations enabled by correlative
big-data studies [86, 87]. Automated computational analysis
andmorphometry of whole-slide images has the unique ability
to investigate tumor microenvironmental drivers of disease
progression—an important aspect that is not covered by any
other platform (Fig. 3a). Genome-wide matched omics data
enables correlations at the chromosome, gene, and nucleotide
levels (Fig. 3b). SCNA, WES, DNA methylation data, RNA-
Seq, miRNA-Seq, reverse phase protein arrays (RPPA), and
metabolomics data cover major levels in the flow of biological
information from DNA to distinct subcellular chemical envi-
ronments. In addition, epigenomics and functional genomics
data obtained from cellular cultures of tumor specimens can be
added to obtain a comprehensive precision medicine chart
(Fig. 3b). The landscape of somatic alterations in malignant
melanoma shows significant focal- and arm-level amplifications
and clefts (Fig. 3c, d). SCNAs by SNP and low-coverage WGS
detected genomic deregulation of many cancer drivers known to
play important roles in melanocyte development and tissue ho-
meostasis [13]. Hotspots of somatic events of individual patient
data can be compared to cancer genome databases [88].
Mutation pattern in combination with three-dimensional protein
structures reveals the mutation distribution of specific functional
regions and can highlight hotspots or oncogenic drivers
[89–92]. The study on efficient detection of genomic drivers
in malignant melanoma identified co-occurrence of amutational
and copy number hotspot on chromosome 7 including the
known BRAF locus [13]. Interestingly, the activating somatic
BRAF(V600E) mutation is accompanied by somatic mutation
and/or somatic copy number amplification of prominent epige-
netic regulators such as enhancer of zeste 2 polycomb repressive
complex 2 subunit (EZH2, KMT6A, Gene ID: 2146), lysine
demethylase 7A (KDM7A, JHDM1D, Gene ID: 80853), and
euchromatic histone lysine methyltransferase 2 (EHMT2,
KMT1C, Gene ID: 10919) [13, 85]. The detailed analysis of
the mutational landscape of BRAF revealed missense mutations
in the ATP-binding site of G466, S467, and G489 as well as in
the activator loop of D594, L597, and K601 in the proximity of
Fig. 3 Precision medicine profile and rational drug targeting of
malignant melanoma. a Whole-slide tumor tissue image of malignant
melanoma shows tumor microenvironment and its impact on
metabolically and mitotically active melanoma cells. b Multiomics data
of tumor specimen is matched with high-throughput functional genomics
data of cellular cultures. The personalized precision medicine chart
shows deregulation of important signaling and epigenetic molecules
across matched data tracks of genomic, epigenomic, transcriptomic,
proteomics, and metabolomics platforms. c Comparison of patient data
with somatic copy number alterations (SCNAs) of melanoma cohort
identifies significant amplifications (red) and d deletions (blue).
Detected somatic alterations of BRAF and EZH2 coincide, fall into
mutational hotspots, and result in gain-of-function oncogenes. The
somatic landscape of ARID1A and ARID2 is characterized by somatic
non-sense and missense mutations, which result in loss of function of a
tumor suppressor complex involved in chromatin remodeling. eRewiring
of metabolism and metabolic signaling affects melanogenesis and tunes
central carbon metabolism to support evasion, proliferation, and survival
of malignant melanoma. f Oncometabolites impact the epigenetic
machinery by blocking or supplying carbons for histone modifiers.
Epigenetic master regulators in cancer control transcriptional activation
of other oncogenes or repression of tumor suppressors. g Personalized
medicine strategies to overcome treatment resistance of malignant
melanoma patients. h Patient profiles of The Cancer Genome Altas
(TCGA) reveal co-occurrence of BRAF and EZH2 hyperactivity
making combination therapy of mitogen-activated kinase inhibitors
(MAPKi) and epigenetic inhibitors (EPIi) viable. As alternative option
if immunotherapy (IMMUNOi) fails due to immune evasion and
suppression of immune receptors, combination therapy of IMMUNOi
and metabolic inhibitors (METABi) is sensible
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residue V600 [13]. EZH2 contains the catalytic histone lysine
methyl transferase subunit of the polycomb repressive complex
2 (PRC2), which plays a role in maintenance of the stem cell-
like state of cancer cells and in the progression of malignant
melanoma [93]. Hyperactivation of EZH2 by somatic mutations
or copy number gain occurs in 20% of melanoma patients and
negatively impacts overall survival [85].
4 Tumor suppressors and chromatin remodeling
complexes carry protective function but impede
simple genotyping
Non-coding, non-sense mutations are of particular importance
in tumor suppressors, since such factors carry gatekeeping and
protective function in healthy tissue. In melanoma, highest
ranking tumor suppressor genes are tumor protein p53
(TP53, Gene ID: 7157), neurofibromin 1 (NF1, Gene ID:
4763), AT-rich interaction domain 2 (ARID2, BAF200,
Gene ID: 196528), AT-rich interaction domain 1A
(ARID1A, BAF250, Gene ID: 8289), cyclin-dependent ki-
nase inhibitor 2A (CDKN2A, P14ARF/P16INK4A, Gene
ID: 1029), and phosphatase and tensin homolog (PTEN,
Gene ID: 5728). In contrast to oncogenic gain-of-function
events, deleterious loss-of-function events of tumor suppres-
sors are usually homozygous but diverse in their molecular
profile. The ATP-fueled chromatin remodeling complex
switch/sucrose non-fermentable (SWI/SNF) [94, 95] around
ARID1A and ARID2 has the ability to make chromatin ac-
cessible for gene expression and for repair enzymes
counteracting UV-induced DNA damage. Similar to PRC2,
the SWI/SNF complex is essential for the self-renewal in
melanocyte development and in pluripotent stem cells. A di-
verse array of somatic copy number deletions and non-sense
mutations of epigenetic regulators ARID1A and ARID2 lead
to dysfunctional chromatin remodeling (Fig. 3d). Such un-
precedented complexity of the mutational landscape of cancer
drivers puts simple targeted, single-nucleotide variation-based
genotyping assays at a disadvantage. In contrast, genome se-
quencing has the ability to capture both breadth and depth of
somatic alterations in cancer. However, calling of SCNAs and
somatic mutations for each patient is just a fraction of the
precision medicine workflow. Only in few rare cases of
well-characterized genomic alterations it is possible to reliably
predict implications at the messenger, protein, and metabolite
levels. For effective precision medicine treatment, systems
biology interpretation, comparison to human mutation, geno-
mics, and variant databases [31, 96–98], functional connec-
tion between different omics platforms, and prediction for
drug response are equally important [99] (Figs. 1b and 4a–d).
5 Oncometabolites connect melanoma metabolism
and epigenetics
No field other than melanoma has better accounted for con-
nections between genetic causation, disease phenotype, and
physical presentation: genomic studies have the ability to
identify links between pigmentation of skin, hair, and eyes,
tissue development, melanogenesis, pigment metabolism, mi-
togenic signaling pathways, ethnicity, gender, age, suscepti-
bility loci, disease risk, initiation, and melanoma progression
(Fig. 4a). Profiling studies of melanoma utilizing metabolo-
mics and fluxomics revealed a distinct decoupling of
Fig. 4 Precision medicine profile and rational drug targeting of
malignant melanoma. a Rewiring of metabolism and metabolic
signaling affects melanogenesis and tunes central carbon metabolism to
support evasion, proliferation, and survival of malignant melanoma. b
Oncometabolites impact the epigenetic machinery by blocking or
supplying carbons for histone modifiers. Epigenetic master regulators in
cancer control transcriptional activation of other oncogenes or repression
of tumor suppressors. c Personalized medicine strategies to overcome
treatment resistance of malignant melanoma patients. d Patient profiles
of The Cancer GenomeAtlas (TCGA) reveal co-occurrence of BRAF and
EZH2 hyperactivity making combination therapy of mitogen-activated
kinase inhibitors (MAPKi) and epigenetic inhibitors (EPIi) viable. As
alternative option, if immunotherapy (IMMUNOi) fails due to immune
evasion and suppression of immune receptors, combination therapy of
IMMUNOi and metabolic inhibitors (METABi) is sensible
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glycolysis and glutamine-fueled TCA cycle in support of hyp-
oxic survival [100–102]. While metabolic rewiring supported
by specific isoforms of metabolic enzymes including hexoki-
nase, phosphoglycerate dehydrogenase, serine methyl trans-
ferase, glycine cleavage complex, pyruvate kinase, pyruvate
dehydrogenase, oxoglutarate dehydrogenase, isocitrate dehy-
drogenase, pyrroline-5-carboxylate reductase, glutamic oxalo-
acetic transaminase, and glutaminase facilitate production of
biosynthetic precursors, metabolites can also have functions in
signaling and epigenetics [99, 103, 104] (Fig. 4a, b).
Overabundance or limitation of onco-metabolites such as
amino- and beta-ketoacids [105–107] are direct suppliers
and controllers of histone methyl modifiers [108]. Mutant
isocitrate dehydrogenase (NADP(+)) 1 (IDH1, Gene ID:
3417) will produce 2-hydroxyglutarate (2HG, (R)-
hydroxyglutarate, PubChem CID: 439391) and modulate his-
tone lysine demethylases (KDMs) known to be central epige-
netic regulators. In contrast, histone lysine methyltransferases
(KMTs) like EZH2 rely on a steady supply of S-adenosyl
methionine (SAM, PubChem CID: 9865604) utilized for his-
tone tri-methylation leading to repression of tumor suppres-
sors [85, 109]. The emphasis of EZH2 in melanoma is en-
hanced by specific loss of other KTMs [108].
6 Rational combination of orthogonally targeted
therapies
The fraction of newly discovered epigenetic players inmelanoma
genomics is striking and indicates environmental implications
beyond UV-induced carcinogenic photoproducts [110]. In con-
trast to genomics, the emerging field of epigenomics represents
only about 2% of the genome-scale studies but grows at a much
higher rate [111]. The co-occurrence of BRAF and EZH2 hyper-
activation [13, 85] as illustrated in the precision medicine case in
melanoma presented above opens new possibilities for targeted
treatment. Mono-therapy with MAPKi (either against BRAF or
MAP2K7) is known to lead to drug resistance and disease pro-
gression. Combination therapies of different MAPKi molecules
are effective but have significant side effects. A precision treat-
ment that takes advantage of the independence of signaling and
epigenetic pathways could combine MAPKi and EPIi (Fig. 4a).
Elevated activity of EZH2 in cancer can be targeted by small-
molecule drugs (e.g., GSK126, PubChem CID 68210102) [112]
and is associated with sensitivity to apoptotic cell death [109].
Transcriptomic profiling showed that several well-known tumor
suppressors such as BCL2 family apoptosis regulator (BOK,
BCL2L9L, Gene ID: 666), N-myc downstream regulated 1
(NDRG1, Gene ID: 10397), and Ras association domain family
member 5 (RASSF5, Gene ID: 83593) are downregulated in
cells with abnormalities in EZH2, which can be reversed by
inhibitor treatment [85]. An in vitro EZH2 drug targeting assay
made it possible to validate genes associated with immune
recognition, cytokine, chemokine, and major histocompatibility
complex class II antigen presentation [85, 113]. Identified target
genes by combination of transcriptomic and ChIP-Seq assess-
ment revealed genes associated with tumor suppression, apopto-
sis, cell differentiation, cell cycle inhibition, and repression of
metastases as well as antigen processing and presentation path-
ways. EZH2 controls cross-talk with natural killer cells suggest-
ing an immunosuppressive effect of EZH2 involving both innate
and adaptive immunity [114]. Cell culture and animal models
with EZH2 inhibitors show significantly decreased spheroid
growths, cell cycle arrest, apoptosis, and tumor regression [85,
109, 114]. EZH2 enhances immune evasion and tumor prolifer-
ation by repressing a defined gene expression program of im-
mune receptor and apoptotic signaling. This raises the question,
whether EPIi or METABi with patients of rewired epigenetics
and tumor metabolism have the ability to support the efficacy of
IMMUNOi. Captivatingly, a metabolic enzyme, lactate dehydro-
genase, central to the Warburg effect in cancer is a negative
prognosticator for IMMUNOi response and predictive biomarker
for overall survival of patients with malignant melanoma [115,
116]. Taken together, patients with somatic activation of EZH2
may benefit from treatment combinations that include inhibitors
of EZH2 [85] (Fig. 4c). Given a more than 60% frequency of
genomic and non-genomic somatic activation of EZH2 in mela-
noma patients, this case of precision medicine might be more
generalizable and synergy between epigenetic and immune
checkpoint inhibition has a strong potential for a broader treat-
ment regimen.
7 The ideal personalized strategy is specific but has
wide coverage
Amajor concern of precision medicine approaches is the gen-
eralizability of identified somatic events and isolated case
studies. Tumor heterogeneity and high background mutation
rate in cancers like melanomas further impede one-dimensional
disease management that can be expected to work for all pa-
tients. Comparisons to genomics databases like TCGA support
the significance of the observed co-occurring signature of
BRAF with epigenetic regulators (Fig. 4d) [117, 118]. EZH2,
cAMP-responsive element binding protein 3 like 2 (CREB3L2,
Gene ID: 64764), and KDM7A are not only significantly co-
amplified due to their genomic proximity (p value below
0.001); their mutational signature shows co-occurrence as well
[13, 85]. In addition, important epigenetic regulators with tu-
mor suppressor function are lost in melanoma at the level of
somatic copy number deletions or inactivating somatic muta-
tions. Taken together, the observed precision medicine signa-
ture representative for any patient with rewired MAPK and
epigenetic regulators is likely to be relevant to the majority of
the melanoma cohort (229 of 287), taking all genomic,
transcriptomic, and proteomic data into consideration (Fig. 4d).
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8 Melanoma subtypes and predominance
of MAPK-related signaling
Genomic insights identified distinct molecular signatures of ma-
lignant melanoma with important consequences for patient strat-
ification (Fig. 5). Mutual exclusivity of oncogenic events in the
MAPK pathway covers about three fourths of the malignant
melanoma patient cohort [13, 23, 25]. On the one hand, melano-
mas with chronic sun-induced damage (CSD) harbor mutations
in KIT proto-oncogene receptor tyrosine kinase (KIT, Gene ID:
3815), NF1, NRAS, and BRAF but typically not
BRAF(V600E), the specific BRAF mutation that commonly
arises in atypical melanocytic neoplasms [119, 120]. On the
other hand, non-CSD melanomas show a predominance of
BRAF(V600E) mutations arising from nevi [121]. Both types
have core activation of the MAPK pathway in common, cover-
ing at least 80% of the melanoma cohort (Fig. 5a). Since
BRAF(V600E) activation requires a T>A transversion at nucle-
otide 1799, BRAF non-CSD mutations do not resemble nucle-
otide transitions typically found in sun-induced melanoma dam-
age arising from cyclobutane pyrimidine dimers (CPDs)
(Fig. 5b). CPDs are DNA photoproducts of joined adjacent py-
rimidines and responsible for the initiation of the predominant
C>T UV melanoma signature mutations [122]. UV-induced re-
active oxygen species have the ability to oxidize melanin to
create melanin carbonyls. This explains why carcinogenic
Fig. 5 Melanoma subtypes and UV signature of mutagenesis in
melanoma drivers. a Melanoma subtypes are divided by (I) genomic
and (II) non-genomic activation of the mitogen-activated protein kinase
(MAPK) pathway. Melanoma with genomic MAPK activation contain
(IA) non-chronic sun-induced damage (non-CSD) melanomas with
BRAF(V600E) mutation (50%) and (IB) chronic sun-induced damage
(CSD) melanomas with mutations of central genes of the MAPK
pathway including KIT, NRAS, NF1, BRAF(non-V600E), MAP2K, or
MAPK (∼30%). Both non-CSD and CSD share subtype (I) and have
genomic activation of the MAPK pathway in common (∼80%). Any
melanoma without genomic activation of MAPK elements is defined as
subtype (II) (∼20%). Subtype (II) melanomas with lowmutational burden
are enriched in driver genes of (IIA) membrane receptors and/or G protein
signaling, (IIB) epigenetic regulators, and/or (IIC) metabolic regulators.
Subtype (II) frequently share effector activation of MAPK signaling by
non-genomic mechanisms. b UV signature of nucleotide transitions in
melanoma is determined by exome-wide genome sequencing.
Percentage of driver mutations caused by UVA (C>A) or UVB (C>T)
are plotted vs the exome-wide sample average percentage. Example
genes a–e provide representative examples of melanoma drivers: i
BRAF, ii RAC1, iii STK11, iv NRAS, and v CDKN2A. The non-CSD
driver gene BRAF contains a high fraction of non-UV mutations
deviating from exome-wide sample average; CSD drivers contain
nucleotide transversions by cyclobutane pyrimidine dimers (CPDs)
responsible for the initiation of the predominant C>T UV melanoma
signature mutations. Tumor suppressor genes with high mutational
burden and co-occurrence with CSD genes can closely reflect the
exome-wide sample average of UV-related base transitions. Oncogenic
drivers are subject to molecular evolution selecting for specific base
transitions, which can cause deviation of the exome-wide sample
average. Structural representation of non-CSD and CSD mutations of
melanoma driver BRAF. Residue V600 in the center of the activator
loop of BRAF is highlighted in purple. The comprehensive somatic
molecular landscape of BRAF in melanoma is illustrated in Figs. 3 and
4. CSD hotspots include the activator loop in pink and the ATP-binding
site in yellow
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CPDs can be generated even after UVexposure of the skin ends
[123]. Both oxidative DNA damage and UV-induced mutation
signatures have an overlapping footprint related to pyrimidine
heterocycle chemistry. Future chemoprevention efforts of malig-
nant melanomamay take advantage of such prevalent molecular
features connecting mutation signature, pigmentation genetics,
and cellular environment [124]. Similar to BRAF, melanoma
driver genes like ras-related C3 botulinum toxin substrate 1
(RAC1, rho family, small GTP binding protein Rac1, Gene
ID: 5879), serine/threonine kinase 11 (STK11, LKB1, Gene
ID: 6794), or NRAS have such a distorted distribution of nucle-
otide transitions, since activation nucleotide transversions can
favor or disfavor the UV melanoma signature. A CSD UV sig-
nature is typically found inmelanoma tumor suppressors such as
CDKN2A resembling the exome average.
9 Activation of the MAPK pathway by genomic
and non-genomic mechanisms
Activation of BRAF alone by somatic mutation, amplifica-
tion, transcriptional upregulation, or post-translational modi-
fication is present inmore than 80% of the patients. In addition
to BRAF(V600E) non-silent, polar replacements in the acti-
vator loop (p.D594G/H/N, p.G596D/R/S p. L597Q/R/S,
p.T599TT, p.K601E/N/T), the glycine-rich ATP binding site
(p.G466A/E/V, p.S467L, p.G469A/E/L/R/S/V), or the protein
interaction surfaces of BRAF activate MAPK signaling
(Fig. 5c). In the case of genomic MAPK activation (subtype
I), the BRAF status as well as signature UVmutations provide
insight into the molecular origin of melanoma. Knowledge of
subtype IA vs IB is of importance for the choice of the drug
regime, where BRAF(V600E) mutations were the prime tar-
get scaffold for small-molecule design [38, 125, 126]. Both
CSD and non-CSD subtypes share genomic activation of core
elements of the MAPK pathway. The remaining non-genomic
MAPK subtype (also referred to as BRAF/NRAS/NF1 wild-
type subtype) predominates in younger individuals with over-
all lower mutation burden and heterogeneous origin.
However, at low frequency, non-genomic MAPK melanoma
drivers are found in pathways of G protein-coupled receptors,
metabolism, or epigenetic signaling (Fig. 5a). Overexpression
of receptor tyrosine kinases platelet-derived growth factor re-
ceptor beta (PDGFRB, PDGFR, Gene ID: 5159) or MET
proto-oncogene (MET, HGFR, Gene ID: 4233) following
BRAF inhibition will reactivate mitogenic and survival path-
ways [52, 53, 127, 128]. A frequent observation in BRAF
inhibitor resistance is coincidence with G protein-, RAS-, or
PI3K-mediated reactivation of theMAPK pathway at the level
of MAP2Ks or MAP3Ks. In addition to altered gene expres-
sion, other non-genomic mechanisms of regulation include
promoter methylation, histone modifications, non-coding
RNAs, posttranslational modification at the protein level, or
metabolic feedback [99]. Importantly, non-genomic MAPK
drivers have the ability to bypass central MAPK molecules
and activate a similar program of MAPK effectors, without
genomic activation of core or upstream factors such as BRAF
in the MAPK pathways.
10 Non-genomic MAPK subtype and oncogenic
signaling in uveal melanoma
There is a striking similarity of the non-genomic MAPK
subtype and oncogenic signaling in uveal melanoma.
Uveal melanomas have less frequent somatic mutations
and SCNAs in a much lower frequency than cutaneous
melanoma. While BRAF and NRAS are usually of wild-
type status [129], somatic mutations and SCNAs affecting
G protein signaling are observed [130, 131]. However, the
non-genomic MAPK program is heterogeneous and diffi-
cult to diagnose and treat, since similar mechanisms to
MAPKi resistance might be utilized [132]. In uveal mela-
noma, combined inhibition of MAP2K1 and AKT results
in synergistic anticancer activity of G protein-mutant tu-
mors. In contrast, BRAF inhibition of the same tumors can
enhance mitogen-activated protein kinase 1 (MAPK1,
ERK, Gene ID: 5594) signaling, emphasizing the impor-
tance of personalized, genotype-based approaches. The ef-
fector program common to genomic MAPK and non-
genomic MAPK subtypes is illustrated by activation of
the RAC1 and AKT signaling axis, as well as activation
of the E2F family transcription factors governing cell cycle
progression. Total mutation burden as well as the fraction
of genome altered are elevated with loss of tumor suppres-
sors. Tumor suppressors exemplify the close connection be-
tween UV-related CPD-mediated nucleotide transversion with
age-related accumulated genomic damage present in CSD
melanoma. However, strict mutual exclusivity of major mela-
noma tumor suppressors NF1, PTEN, TP53, or CDKN2A to
non-CSD melanomas is not observed, possibly due to parallel
and/or redundant signaling. Therefore, loss of tumor suppres-
sors does not suggest clinically actionable stratification or jus-
tify independent subtypes in this framework.
11Major signaling pathway alterations in melanoma
By taking all available data levels from genomics to pro-
teomics into consideration, it is possible to prioritize sig-
naling pathways that are consistently altered in malignant
melanoma (Fig. 6). The MAPK kinase pathway presents
itself as recurring theme. Intriguingly, driver mutations are
not organized in a strict mutually exclusive fashion (Fig. 6a).
While signals are processed by subsequently operated NRAS
and BRAF switches which are mutually exclusive, there are
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alternative modes of activation and therefore co-occurrence of
driver events in the subsequent kinase cascade. Such alterna-
tive modes coincide with re-wiring of pathways observed in
melanoma drug resistance, where small molecules fail to
completely block signaling, despite upstream kinases being
dead (Fig. 6a, b). The picture is further complicated by inter-
connected signals of MAPK, RAC, AKT, PI3K, and NGFR
pathways (Fig. 6b, c). RAC1 has been recognized as a fre-
quently mutated melanoma gene by next-generation sequenc-
ing studies [21]. RAC1 mutations are present in all melanoma
subtypes, which can be explained by its position at the cross-
roads of KIT/NRAS/BRAF/MAPK signaling and the
PI3K/PTEN/AKT axis (Fig. 7). Therefore, RAC1 activation
is independent of BRAF blockage and is able to induce mito-
genic events.
12 Signaling maps of melanoma and melanogenesis
highlight predominant oncogenes and tumor
suppressors
Melanocytes are derived from a neuroectodermal lineage provid-
ing them with a unique gene-expression signature and making
them distinct from epithelial or non-epithelial cancers. Part of the
melanocyte program is migration from the neural crest into ec-
toderm, differentiation, and clonal propagation of pigment-
producing cells. Melanoma cells express neuroectodermal mark-
er transmembrane receptors such as nerve growth factor receptor
(NGFR, CD271, neurotrophin receptor, Gene ID: 4804), which
has been found to be amarker formelanoma-initiating cells [133]
(Fig. 6c). Melanogenesis and melanoma progression are inter-
connected by activation of wingless (WNT), melanocortin 1
Fig. 6 Pathway analysis of genomic alterations in malignant melanoma.
a Oncogenic alterations of MAPK pathway is illustrated by somatic
mutations, SCNAs, and transcriptional alterations (from inner box to
outer box; see legend). Genomic activation and inactivation are shown
in red and blue, respectively. Genomic co-occurrence and mutual
exclusivity points to multiple parallel signals within pathway. b MAPK
pathway. c PI3K pathway. dWNT and G protein signaling. e Cell cycle,
senescence, and apoptotic signaling. Signaling maps of melanoma and
melanogenesis highlight predominant oncogenes and tumor suppressors,
in red and blue, respectively
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receptor (MC1R, Gene ID: 4157), andmelanogenesis-associated
transcription factor (MITF, Gene ID: 4286) signaling. Not sur-
prisingly, genomic profiles of melanoma and melanocytes over-
lap in transcriptional drivers of cellularmobility and proliferation,
responsible for invasiveness and homing of melanoma
[134–138] (Fig. 6d). Deregulation of melanogenesis can either
contribute to dedifferentiation with loss of pigmentation compa-
rable to a mesenchymal-epithelial transition, or elevated pigmen-
tation and mitogenesis. Tyrosinase is essential for pigment syn-
thesis in melanocytes and is an established antigen in melanoma.
The roles of pigmentation in melanoma can be paradoxical: ele-
vated tyrosinase expression can induce an auto-immune response
leading to metastatic regression. Once tyrosinase-negative cells
are able to escape this immune recognition, relapse and disease
progression occur. Tumor suppressors are important safeguards
of cells. The CDKN2A gene locus is frequently affected by copy
number loss, non-sense mutations, and splicing aberration. Its
two gene products, P14ARF and P16INK4A, control TP53
and RB transcriptional corepressor 1 (RB1, retinoblastoma
protein 1, Gene ID: 5925) mediating cell cycle signaling [139,
140], respectively. Various genomic and non-genomic changes
can lead to a deregulated cell cycle clock and apoptotic signaling
(Figs. 6e and 7a–e). Inactivating mutations or promoter methyl-
ation of tumor suppressor RB1 and cell cycle inhibitors overwrite
cell cycle checkpoints. Amplification and transcriptional upreg-
ulation of cyclins and cyclin-dependent kinases lead to RB1
phosphorylation and cell cycle progression. The tumor
suppressor and pocket protein RB1 usually restricts the cell cycle
progression by protecting and inhibiting the oncogenic E2F tran-
scription factor family. Similarly, amplification and transcription-
al upregulation of E2F transcription factors promote the cell cycle
(Fig. 7f). Captivatingly, E2Fs are engaged in feedback loops by
controlling cell cycle, anti-apoptotic survival pathways, and epi-
genetic regulators. E2F transcription factors including their main
representative E2F1 are upstream regulators of the epigenetic
polycomb complex around EZH2 constituting an important link
to maintenance of the stem cell-like state of melanoma cells
[141]. In addition, EZH2 has the ability to interfere with apopto-
tic pathways and immune evasion by repressing tumor suppres-
sors, immune, cytokine and chemokine receptors (Fig. 6e).
Signaling maps in combination with precision medicine profiles
of cancer patients provide rational insights in treatment options
and highlight predominant hubs of oncogenes and tumor sup-
pressors (Figs. 3, 4, 5, 6, and 7).
13 Conclusion
Melanoma precision medicine has significantly benefitted from
large-scale sequencing efforts. Exome-wide and genome-wide
sequencing initiated genomic biomarkers, targeted therapeutics,
and encouraging clinical results. Collaborative, multiplatform
genome sequencing approaches in cancer will be integrated into
clinical practice in the near future. Molecular systems biology
Fig. 7 Molecular signatures and genomic alterations in malignant
melanoma. Oncogenic alterations of a MAPK pathway; b BRAF at the
mutational level (MUT), the protein level (PROT), the level of somatic
copy number alterations, and at the gene expression level; c tumor
suppressors PTEN and TP53 correlating with total mutation burden and
age at diagnosis; d the PI3K/PTEN/AKT axis; e cell cycle inhibitors and
tumor suppressors CDKN2A, CDKN2B, and RB1 correlating with total
mutation burden and fraction of the genome altered; and f the E2F family
of cell cycle-related transcription factors. Somatic mutations are marked
as dots. SCNAs are highlighted as red and blue bars for amplification and
loss, respectively. Significant deviation of mRNA gene expression by
more than two standard deviations is marked with transparent box for
each skin cutaneous melanoma (SKCM) patient of The Cancer Genome
Atlas (TCGA) cohort
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insights will impact prevention, diagnosis, and management of
melanoma. Building a precision medicine framework is an in-
vestment in improved diagnostics and treatment protocols.
Advanced molecular, high-throughput platforms fuel systems
biology interpretation and enable novel genotype-phenotype as-
sociations in human melanoma. Cancer precision medicine still
has to overcome challenges to promote the effective integration
of genomic technology into clinical oncology practice.
Melanoma is either characterized by frequent genomic alterations
or genotypic heterogeneity. Therefore, acquired genomic preci-
sion data requires integration with cancer databases and clinical
statistics. The objective is to distinguish between cancer drivers
with clinically actionable targets or phenotypically neutral events,
so that the treating precision medicine team can prioritize which
clinical decisions should be pursued in order to provide cancer
care that is personalized to the unique genome of the patient.
Currently approved mono- and combination therapies are prom-
ising, and molecular insights from precision medicine have the
ability to suggest orthogonal treatment targeting epigenetics and
metabolism to overcome drug resistance and immune evasion.
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